1176040-39-3

Upstream product

• 50-00-0 formaldehyd 
• 65964-60-5 2-para-tolylimidazo[1,2-a]pyridine 
• 107-21-1 ethylene glycol 
• 122-00-9 para-methylacetophenone 
• 142016-38-4 2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde 
• 619-41-0 4-(bromoacetyl)toluene 

Downstream Products

• 1417910-25-8 C₁₅H₁₃N₅ 
• 1417910-41-8 3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)-2-p-tolyl-1H-imidazo[1,2-a]pyridine 
• 1417910-43-0 2-p-tolyl-3-((4-p-tolyl-1H-1,2,3-triazol-1-yl)methyl)-1H-imidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

KIO4-mediated Selective Hydroxymethylation/Methylenation of Imidazo-Heteroarenes: A Greener Approach

Herein, we report a KIO4-mediated, sustainable and chemoselective approach for the one-pot C(sp2)?H bond hydroxymethylation or methylenation of imidazo-heteroarenes with formaldehyde, generated in situ via the oxidative cleavage of ethylene glycol or glycerol (renewable reagents) through the Malaprade reaction. In the presence of ethylene glycol, a series of 3-hydroxymethyl-imidazo-heteroarenes was obtained in good to excellent yields. These compounds are important intermediates to access pharmaceutical drugs, e.g., Zolpidem. Furthermore, by using glycerol, bis(imidazo[1,2-a]pyridin-3-yl)methane derivatives were selectively obtained in good to excellent yields.

Exploration of the CuAAC reaction for the synthesis of novel 3-(triazol-1-yl)methyl-imidazo[1,2-a]pyridines

The archetypical CuAAC click chemistry is explored to assemble diverse 3-(triazol-1-yl)methyl-imidazo[1,2-a]pyridines. The approach is simple, general, and environmentally benign to generate a library of novel triazolo-imidazo[1,2- a]pyridine derivatives in good yield (30-90%).

IMIDAZOPYRIDINE COMPOUNDS

The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.